Curevo Vaccine Announces Interim Results of Phase I Clinical Trial of CRV-101

SEATTLE–(BUSINESS WIRE)–Curevo, Inc., a Seattle-based biotechnology company invested in by GC Pharma, one of the largest therapeutic protein manufacturers in the world, has announced encouraging preliminary Phase I safety and tolerability results of their Shingles vaccine candidate, CRV-101. Interim trial results demonstrating a promising safety and tolerability profile of the vaccine in 90 healthy adults ≥18 to <50 were presented…

GC Pharma to Establish Curevo

GC Pharma to Establish Curevo – a Seattle-based New Company Dedicated to Development of New Vaccines GC Pharma, IDRI and MIBR Bringing Together to Develop Innovative Vaccines GC Pharma (formerly known as Green Cross Corporation) (KRX: 006280), a South Korean biopharmaceutical company, today announced the establishment of Curevo Inc. (“Curevo”). The newly established Seattle-based company’s goal is to support GC…